Finance

Lists
RCKT:NASDAQ
Rocket Pharmaceuticals Inc
2,30 USD
0,00%
(0,00) 1D
2,26 USD
-1,74% (-0,040)
Pre-market
Closed: 13-ноя., 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RCKT...
Mkt. cap
256,82 млн
Avg. vol.
1,94 млн
Volume
11,63 миң
52-wk high
5,45 USD
52-wk low
2,16 USD
EPS
-0,16 USD
Beta
0,51
Shares outstanding
111,66 млн
No. of employees
202
Mkt. cap
256,82 млн
Avg. vol.
1,94 млн
Volume
11,63 миң
52-wk high
5,45 USD
52-wk low
2,16 USD
EPS
-0,16 USD
Beta
0,51
Shares outstanding
111,66 млн
No. of employees
202
News stories
From web sources and news partners
Investing.com Nigeria
Investing.com Nigeria
·
17 саат мурун
Form 144 ROCKET PHARMACEUTICALS For: 15 November By Investing.com
About Rocket Pharmaceuticals Inc
CEO-
Employees202
Founded1999
HeadquartersКранбери Тауншип, Нью Джерси, Америка Кошмо Штаттары
SectorHealth Care
Industry-
Analyst ratings
Based on 10 analysts giving stock ratings to RCKT in the past 3 months
Buy
Buy
7
Hold
3
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for RCKT in the last 3 months.
Highest
Current 2,30 USD
15,00 USD (+552,17%)
Average
9,20 USD (+300,00%)
Lowest
4,00 USD (+73,91%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Zemansky
Bank of America Securities
Buy
Reiterated
10,00 USD
+334,8%
11/16/2026
Mani Foroohar
Leerink Partners
Hold
Reiterated
4,00 USD
+73,9%
11/13/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
10,00 USD
+334,8%
11/13/2026
Gil Blum
Needham
Buy
Maintained
9,00 USD
+291,3%
11/13/2026
Yun Zhong
Wedbush
Buy
Maintained
12,00 USD
+421,7%
11/13/2026
Michael Ulz
Morgan Stanley
Hold
Maintained
5,00 USD
+117,4%
11/13/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
15,00 USD
+552,2%
11/09/2026
Richard Law CFA
Goldman Sachs
Hold
Upgraded
4,00 USD
+73,9%
10/08/2026
Patrick Dolezal
LifeSci Capital
Buy
Maintained
12,00 USD
+421,7%
10/02/2026
Keay Nakae
Chardan Capital
Buy
Reiterated
11,00 USD
+378,3%
09/15/2026
Tara Bancroft
TD Cowen
Hold
Maintained
-
-
08/10/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
11,00 USD
+378,3%
05/10/2026
Tessa Romero
J.P. Morgan
Sell
Maintained
-
-
04/02/2026
Unknown Analyst
Canaccord Genuity
Buy
Maintained
10,00 USD
+334,8%
03/02/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
02/26/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
29,35 млн
31,45 млн
29,50 млн
31,17 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14,68 млн
17,06 млн
17,42 млн
19,79 млн
Operating expense
44,03 млн
48,51 млн
46,92 млн
50,96 млн
Total operating expenses
44,03 млн
48,51 млн
46,92 млн
50,96 млн
Operating income
-44,03 млн
-48,51 млн
-46,92 млн
-50,96 млн
Other non operating income
-
-
-
-
EBT including unusual items
-42,54 млн
-47,59 млн
131,84 млн
-49,18 млн
EBT excluding unusual items
-43,81 млн
-48,82 млн
-47,05 млн
-50,42 млн
Income tax expense
-
-
8,62 млн
54,00 миң
Effective tax rate
-
-
6,54%
-0,11%
Other operating expenses
-
-
-
-
Net income
-42,54 млн
-47,59 млн
123,21 млн
-49,23 млн
Net profit margin
-
-
-
-
Earnings per share
-0,38
-0,42
-0,38
-0,43
Interest and investment income
690,00 миң
161,00 миң
347,00 миң
1,01 млн
Interest expense
-473,00 миң
-473,00 миң
-473,00 миң
-473,00 миң
Net interest expenses
217,00 миң
-312,00 миң
-126,00 миң
541,00 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-41,81 млн
-46,36 млн
-44,82 млн
-48,94 млн
Gain or loss from assets sale
-
-
-178,19 млн
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору